KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2025)

Castle Biosciences' Amortization - Intangibles history spans 5 years, with the latest figure at $10.5 million for Q4 2025.

  • For Q4 2025, Amortization - Intangibles rose 144.21% year-over-year to $10.5 million; the TTM value through Dec 2025 reached $34.8 million, up 214.65%, while the annual FY2025 figure was $34.8 million, 213.86% up from the prior year.
  • Amortization - Intangibles for Q4 2025 was $10.5 million at Castle Biosciences, up from $2.3 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $20.1 million in Q1 2025 and bottomed at $256000.0 in Q2 2021.
  • The 5-year median for Amortization - Intangibles is $2.2 million (2022), against an average of $3.4 million.
  • The largest YoY upside for Amortization - Intangibles was 813.64% in 2025 against a maximum downside of 14.74% in 2025.
  • A 5-year view of Amortization - Intangibles shows it stood at $958000.0 in 2021, then skyrocketed by 134.76% to $2.2 million in 2022, then increased by 3.11% to $2.3 million in 2023, then soared by 85.42% to $4.3 million in 2024, then surged by 144.21% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Amortization - Intangibles are $10.5 million (Q4 2025), $2.3 million (Q3 2025), and $2.0 million (Q2 2025).